P2RY6+ tumor-associated macrophages as a therapeutic target: suppressing tumor growth and enhancing chemosensitivity in triple-negative breast cancer Authors: Xin Wang, Mingyue Ma, Mingyu Zhang, Han Lu, Ying Liu, Yang Zhou, Bing Han Published: 2026 ABSTRACT AbstractBackgroundTriple-negative breast cancer (TNBC) harbors an immunosuppressive tumor microenvironment dominated by tumor-associated macrophages (TAMs). P2RY6, a UDP-sensitive purinergic receptor, is implicated in immune modulation, but its functional role in TNBC TAMs remains elusive.MethodsThe clinical relevance of P2RY6+ TAMs was assessed via bioinformatics, tissue microarrays, and survival analysis. In vitro, P2RY6 function in macrophage polarization, signaling, and paracrine regulation of TNBC cells was evaluated using genetic/pharmacological approaches, RNA sequencing, calcium imaging, and secretome analysis. The downstream effector S100A9 and its receptor (TLR4/RAGE)-NF-κB axis in TNBC cells were validated. Orthotopic TNBC mouse models were used to evaluate therapeutic targeting of P2RY6 and S100A9 in vivo.ResultsP2RY6⁺ TAM infiltration correlates with poor prognosis in TNBC patients. UDP activation of P2RY6 drives M2-like macrophage polarization via the PLC-IP3-Ca2+/CREB1 pathway, leading to transcriptional upregulation and secretion of S100A9. Macrophage-derived S100A9 binds TLR4/RAGE on TNBC cells, activates NF-κB signaling, and promotes tumor proliferation. Genetic or pharmacological inhibition of P2RY6, or neutralization of S100A9, suppresses TNBC growth in vitro and in vivo, and synergizes with chemotherapy to enhance antitumor efficacy.ConclusionsOur study unveils a UDP-P2RY6-S100A9 paracrine axis wherein P2RY6⁺ TAMs foster an immunosuppressive and pro-tumorigenic niche in TNBC. This axis represents a novel therapeutic target to disrupt TAM-tumor crosstalk and overcome chemoresistance in TNBC.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13402-026-01239-w.Keywords: Purinergic receptors, Cancer neuroscience, Macrophage polarization, Tumor immunity Introduction Breast cancer remains the most common malignancy and the second leading cause of cancer-related mortality among women worldwide [1]. Among breast cancer subtypes, triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, exhibits the poorest prognosis due to a lack of effective treatment options [2, 3]. TNBC is refractory to endocrine therapy and molecular-targeted agents, and is frequently characterized by suboptimal response to chemotherapy and high rates of recurrence [4]. Therefore, elucidating the molecular mechanisms driving TNBC progression is crucial for identifying novel therapeutic targets. Macrophages represent the most prevalent tumor-infiltrating immune cells and the dominant innate immune population within the tumor microenvironment (TME) of TNBC [5]. Tumor-associated macrophages (TAMs) act as pivotal regulators of tumor development, driving both TNBC progression and chemotherapy resistance. Owing to the diversity and plasticity, macrophages undergo polarization, a process through which they adopt context-specific phenotypic and functional states in response to cues from the TME [6]. The dynamic reprogramming of TAMs critically influences tumor growth. Accordingly, a deeper understanding of the crosstalk between TNBC cells and TAMs, along with the elucidation of underlying molecular mechanisms, is essential for uncovering novel therapeutic targets. Tumor cells and other cells within the TME exploit neurotransmitter signaling to promote malignant progression. Extracellular nucleotides, functioning as neurotransmitters, are extensively implicated in tumor progression [7, 8]. Under physiological conditions, extracellular nucleotides are maintained in a state of homeostatic balance [9], whereas in cancer, their concentrations become elevated within the TME [10]. The increase results from both passive release due to cell damage, triggered by inflammation, hypoxia, chemotherapy, or tissue destruction from tumor invasion, and active secretion from viable or apoptotic cells via mechanisms such as vesicular exocytosis, membrane transporters, or other membrane-associated pathways [11]. P2 purinergic receptors are activated by extracellular nucleotides in the tumor setting [12]. The receptors significantly promote tumor progression by coordinating intercellular communication and serve as key mediators of cellular crosstalk within tumors [13, 14]. P2RY6, a member of the P2Y receptor family, displays maximal sensitivity to UDP and is implicated in disease risk due to its diverse functional roles across multiple physiological systems [15, 16]. Nevertheless, its precise involvement in the progression of TNBC remains poorly understood. S100 calcium-binding protein A9 (S100A9) is a versatile molecule mediates cellular crosstalk within the TME and exhibits the function in both tumor progression and immune regulation [17]. S100A9 exhibits tumor-promoting activities primarily through interactions with its major receptors, toll-like receptor 4 (TLR4) and receptor for advanced glycation endproducts (RAGE) [18]. Elevated S100A9 expression is associated with advanced disease and poor prognosis in various cancers, thus making it a focus of ongoing investigation in the field of cancer immunotherapy. In this work, we first profiled neurotransmitter receptors and neuroactive ligand‑receptors that are significantly expressed in TAMs and associated with TNBC prognosis, identifying P2RY6 as a putative functional receptor. Subsequently, we demonstrate that UDP-specific activation of P2RY6 promotes macrophage polarization towards an M2 state and induces S100A9 expression. Acting in a paracrine manner, S100A9 binds to the TLR4/RAGE receptors on TNBC cells, thereby stimulating tumor proliferation. Notably, targeting P2RY6 markedly suppressed tumor growth and enhanced chemosensitivity, suggesting a potential therapeutic strategy for TNBC. Materials and methods Cell culture and reagents The human TNBC cell lines MDA-MB-468 (RRID: CVCL_0419) and MDA-MB-231 (RRID: CVCL_0062), the mouse TNBC cell line 4T1 (RRID: CVCL_0125), the human monocytic cell line THP1 (RRID: CVCL_0006), the HEK 293T cell line (RRID: CVCL_0063) and the mouse monocyte-macrophage cell line RAW264.7 (RRID: CVCL_0493) were obtained from Shanghai Cell Biological Institute of the Chinese Academy of Science (Shanghai, China). Cell line authentication was performed via short tandem repeat (STR) profiling, with all cultures confirming mycoplasma-free status using the MycoAlert Detection Kit (Lonza) within three months post resuscitation. All cell lines were cultured in either RPMI-1640 or DMEM medium, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin, and incubated at 37 ℃ in a humidified 5% CO₂ atmosphere. UDP (P2RY6 agonist, 19817-91-5) was purchased from Abcam (USA). MRS2578 (HY-13104), recombinant human S100A9 (rhS100A9; HY-P70532), U-73122 (HY-13419), 2-APB (HY-W009724), BAPTA-AM (HY-100545), TAK-242 (HY-11109), FPS-ZM1 (HY-19370) and 666-15 (HY-101120) were purchased from MedChemExpress (USA). Bioinformatics analysis The single-cell data utilized in this study were acquired from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/geo/). Specifically, breast cancer single-cell RNA sequencing (scRNA-seq) data were derived from the dataset GSE176078 [19], which comprises samples from 11 estrogen receptor-positive patients, 5 human epidermal growth factor receptor 2-positive patients, and 10 TNBC patients. All statistical analyses were performed using R software (version 4.3.0). Cellular interactions were analyzed using the “CellChat” R package (version 1.1.3). Patient samples TNBC specimens were obtained from 29 patients diagnosed with invasive breast cancer who underwent surgical resection at the First Hospital of Jilin University between 2016 and 2019 for tissue microarray construction. The median patient age was 54 years (range: 42-71 years). All specimens were collected after obtaining informed consent. This study was conducted in compliance with the principles of the Declaration of Helsinki. All enrolled patients had complete follow-up data, which included demographic characteristics (age and menopausal status), surgical records (tumor size and extent of invasion), pathological findings (molecular subtype, tumor stage, lymph node status, and prognosis), as well as documentation regarding recurrence and metastatic events. The use of clinical samples and associated data was approved by the Institutional Review Board and Ethics Committee of the First Hospital of Jilin University (Approval No. 2023-727). Immunohistochemistry (IHC) staining Tumor tissue samples were paraffin-embedded and cut into 5 μm-thick sections. The sections were deparaffinized and rehydrated through a graded series of xylene and ethanol, after which antigen retrieval was conducted using citrate buffer (G1202, Servicebio, China) at 100 °C for 10 min. The slides were then allowed to cool naturally to room temperature. Subsequently, endogenous peroxidase activity was quenched by treating the sections with 3% hydrogen peroxide solution (88597, Sigma-Aldrich, China) for 30 min at room temperature. Non-specific binding sites were blocked by incubating the sections with 10% bovine serum albumin (BSA) (GC305006, Servicebio, China) for 1 h at room temperature. The sections were then incubated with primary antibodies at 4 °C overnight. Following this, HRP-conjugated secondary antibodies were applied and incubated for 1 h at room temperature. Color development was carried out using a DAB (3,3′-diaminobenzidine) substrate kit (SB-D6077, Share-Bio, China), and the sections were counterstained with hematoxylin. Following staining, sections were dehydrated through a graded ethanol series and cleared in xylene to remove moisture and enhance tissue transparency. All slides were examined and imaged using a microscope. Image acquisition was performed under consistent settings, and staining intensity was quantitatively assessed. Two independent researchers evaluated the stained sections in a blinded manner. Antibodies used include P2RY6 (APR-011, 1:500, Alomone labs, RRID: AB_2040082), TLR4 (66350-1-Ig, 1:200, Proteintech, RRID: AB_2881730), RAGE (66833-1-Ig, 1:200, Proteintech, RRID: AB_2882176), Ki67 (27309-1-AP, 1:2000, Proteintech, RRID: AB_2756525), cleaved caspase-3 (CC3) (25128-1-AP, 1:200, Proteintech, RRID: AB_3073913), and the secondary antibodies, Goat anti-rabbit IgG (H + L) cross-adsorbed secondary antibody, HRP (G-21234, 1:2000, Thermo Fisher Scientific, RRID: AB_2536530), Goat anti-mouse IgG (H + L) cross-adsorbed secondary antibody, HRP (G-21040, 1:2000, Thermo Fisher Scientific, RRID: AB_2536527). Immunofluorescence For immunofluorescence analysis of cells, cultures were fixed with 4% paraformaldehyde (P0099, Beyotime, China) and subsequently permeabilized with 0.1% Triton X-100 (P0096, Beyotime, China). For tissue immunofluorescence, paraffin-embedded human tumor sections were deparaffinized, rehydrated, and underwent antigen retrieval. Following these preparations, both cell and tissue samples were blocked with 10% BSA (GC305006, Servicebio, China) for 1 h at room temperature and then incubated with primary antibodies overnight at 4 °C. After washing three times with Tris-buffered saline (TBS; G0001, Servicebio, China), the sections were incubated in the dark with fluorescence-conjugated secondary antibodies for 1 h at room temperature. Upon completion of sequential tyramide signal amplification (TSA; abs50015, Absin, China) cycles on the tissue sections, the next antibody was applied following the same protocol as described previously. Following the final TSA cycle, nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; G1012, Servicebio, China) for 5 min. Images were captured using a confocal microscope (Leica, Germany). The primary antibodies were as follows: P2RY6 (APR-011, 1:500, Alomone labs, RRID: AB_2040082), CD163 (93498, 1:200, Cell Signaling Technology, RRID: AB_2800204), EPCAM (2929, 1:1000, Cell Signaling Technology, RRID: AB_2098657), TLR4 (66350-1-Ig, 1:200, Proteintech, RRID: AB_2881730), RAGE (66833-1-Ig, 1:200, Proteintech, RRID: AB_2882176). The secondary antibodies were as follows: Goat anti-rabbit IgG (H&L)-Alexa Fluor 647 (RS3811, 1:200, ImmunoWay, RRID: AB_2938759), Goat anti-mouse IgG (H&L)-AbFluor 488 (RS3208, 1:200, ImmunoWay, RRID: AB_3206263). Macrophage polarization assay To initiate the formation of macrophages, THP1 cells were treated with phorbol myristate acetate (PMA; 100 ng/mL) (HY-18739, MedChemExpress, USA) for 24 h. For polarization into M1-like or M2-like phenotypes, the resulting macrophages were then stimulated for 48 h with either lipopolysaccharide (LPS; 100 ng/mL) (00-4976-93, Thermo Fisher Scientific, USA) combined with human interferon-γ (IFN-γ; 50 ng/mL) (300-02, Thermo Fisher Scientific, USA), or with human IL-4 (50 ng/mL) (200-04, Thermo Fisher Scientific, USA) and human IL-13 (50 ng/mL) (200-13, Thermo Fisher Scientific, USA), respectively. For RAW264.7 macrophage polarization, cells were incubated for 48 h under the following conditions: for M1 polarization, with lipopolysaccharide (LPS; 100 ng/mL) (00-4976-93, Thermo Fisher Scientific, USA) plus mouse interferon-γ (IFN-γ; 50 ng/mL) (315-05, Thermo Fisher Scientific, USA); for M2 polarization, with mouse IL-4 (50 ng/mL) (214-14, Thermo Fisher Scientific, USA) and mouse IL-13 (50 ng/mL) (210-13, Thermo Fisher Scientific, USA). The expression of polarization markers was assessed by qRT‑PCR. For M1-like macrophages, we detected CD86 and iNOS in THP1 cells (or Cd86 and inos in RAW264.7 cells) [20]. For M2-like macrophages, we examined CD206, ARG1, and TGFB in THP1 cells (or Cd206, Arg1, and Tgfb in RAW264.7 cells). Cell proliferation assays For the Cell counting kit-8 (CCK-8) assay, cells in the logarithmic growth phase were harvested via trypsinization and centrifugation, counted, and seeded into 96-well plate. Following treatment, 10 µL of CCK-8 reagent (SB-CCK8, Share-Bio, China) was added to each well, and the plates were incubated at 37 °C for 1 h. Absorbance was measured at 450 nm using a microplate reader to evaluate cell viability and proliferation. Each condition was assayed with at least three replicates per time point. For the colony formation assay, 1 × 10³ cells per well were plated in 6-well plates with complete medium (10% FBS) and cultured for 10-14 days to facilitate colony formation. The medium was refreshed every 3 days. Once visible colonies had formed, the cells were washed with PBS, fixed with 4% paraformaldehyde, and stained with crystal violet. After rinsing with PBS, colonies were quantified using image analysis software. Statistical comparisons of colony formation were made across experimental groups. For the EdU assay, cell proliferation was assessed using an EdU kit (C0071S, Beyotime, China). Briefly, 2 × 10⁴ cells were seeded per well in 24-well plates and incubated overnight before treatment. Cells were pulsed with 10 µM EdU for 2 h, then fixed, permeabilized, and incubated with the Click reaction cocktail for 30 min at room temperature in the dark. Nuclei were counterstained with Hoechst 33342 for 10 min at room temperature protected from light. Images were captured using a fluorescence microscope, and the proliferation rate was determined as the percentage of EdU-positive cells relative to the total number of Hoechst-stained nuclei. Cell-based conditional medium To examine the effects of macrophage polarization on tumor cell proliferation, PMA-primed THP1 or RAW264.7 cells were cultured in 60 mm dishes. Following incubation, the supernatants were collected via centrifugation and passed through a 0.22 μm filter. The filtered supernatant was combined with an equal volume of fresh RPMI-1640 or DMEM to generate conditioned medium. Tumor cells were plated in 96-well and 24-well plates and subsequently cultured in the conditioned medium before being subjected to CCK-8 and EdU assays. Cell transfection Cells were seeded in 6-well plates and transiently transfected with CALNP™ RNAi in vitro (DN001, D-Nano Therapeutics, China) following the manufacturer’s protocol. The small interfering RNAs (siRNAs) were obtained from Zorinbio (Shanghai, China), and the sequences are listed as follow: si-P2RY6-1: UUGCUUGAAGUUCUCGCGGTT, si-P2RY6-2: UAGUUGUAGAUGAGCAGGGTT, si-P2RY6-3: UGUGAGUUUCUGUAGGAGCTT, si-P2ry6-1: UUGCGCUGGAUGCCUGUGGTT, si-P2ry6-2: UAGUUAUAGAUAAGUAGGGTT, si-P2ry6-3: UUGUAGGCAGCAGCGAAGGTT, si-NC: ACGUGACACGUUCGGAGAATT. RNA isolation and quantitative real-time PCR Total RNA was extracted using the Rapid RNA Isolation Kit for Cells (SB-R001, Share-Bio, China). RNA concentration was measured with a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, USA). cDNA was then synthesized using the All-in-One First-Strand Synthesis MasterMix (with dsDNase) (SB-RT001, Share-Bio, China). Quantitative real-time PCR (qRT-PCR) was performed on a ViiA7 Real-Time PCR System (Applied Biosystems, USA) using SYBR Green qPCR Master Mix (SB-Q204, Share-Bio, China) under the following cycling protocol: initial denaturation at 95 °C for 30 s, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s. β-ACTIN was used as the internal control. The primer sequences employed for qRT-PCR are provided in Supplementary Table 1. Western blot Cells were lysed on ice for 15 min with RIPA buffer (WB3100, New Cell & Molecular Biotech, China) supplemented with 1% protease and phosphatase inhibitor mixture (P002, New Cell & Molecular Biotech, China). The lysates were centrifuged at 12,000× g for 20 min at 4 °C, and the supernatant was collected. Protein extracts were combined with 5× SDS-PAGE loading buffer (WB2001, New Cell & Molecular Biotech, China), resolved on 10% SDS-polyacrylamide gels, and electrophoretically transferred to the nitrocellulose filter membrane (FFN02, Beyotime, China). After blocking with 5% non-fat milk (P0216, Beyotime, China) for 1 h, the membranes were incubated with specific primary antibodies at 4 °C overnight. The following day, membranes were probed with HRP-conjugated secondary antibodies for 1.5 h at room temperature. Protein bands were visualized using enhanced chemiluminescence (ECL) reagent (P10100, New Cell & Molecular Biotech, China), with β-ACTIN used as a loading control. The following antibodies were used: P2RY6 (APR-011, 1:500, Alomone labs, RRID: AB_2040082), NF-κB (8242, 1:1000, Cell Signaling Technology, RRID: AB_10859369), p-NF-κB (Ser536) (3033, 1:1000, Cell Signaling Technology, RRID: AB_331284), β-ACTIN (60009-1-Ig, 1:20000, Proteintech, RRID: AB_2687938), CREB1 (67927-1-Ig, 1:5000, Proteintech, RRID: AB_2918679), p-CREB1 (Ser133) (81871-1-RR, 1:5000, Proteintech, RRID: AB_2935430); and the species-specific secondary antibodies, Goat anti-rabbit IgG (H + L) cross-adsorbed secondary antibody, HRP (G-21234, 1:2000, Thermo Fisher Scientific, RRID: AB_2536530), Goat anti-mouse IgG (H + L) cross-adsorbed secondary antibody, HRP (G-21040, 1:2000, Thermo Fisher Scientific, RRID: AB_2536527). ELISA assay After THP1 cells were incubated in serum-free medium for 24 h, cell supernatants were collected, clarified by centrifugation, and used immediately. Supernatant volumes were normalized to cell number. S100A9 levels in the culture medium were quantified using a human S100A9 ELISA kit (CSB-E11834h, CUSABIO, China) according to the manufacturer’s instructions. RNA sequencing Total RNA was isolated from THP1 cells in the si-NC + UDP and si-P2RY6 + UDP groups (n = 3), and MDA-MB-468 cells in the control and rhS100A9 (1 µg/mL) (HY-P70532, MedChemExpress, USA) groups (n = 3) using TRIzol reagent (15596026, Thermo Fisher Scientific, USA) following the manufacturer’s protocol. The RNA was subsequently enriched and used to prepare sequencing libraries. These libraries were sequenced on an Illumina Novaseq 6000 platform to generate an expression matrix. Gene expression levels were quantified using the Fragments Per Kilobase per Million (FPKM) method, and read counts for individual genes were derived using featureCounts. Transcriptome sequencing services were provided by OBiO Technology Corp., Ltd. (Shanghai, China). Gene Set Enrichment Analysis (GSEA) was performed using GSEA software (V4.1). The RNA-seq data in this study were deposited in the Sequence Read Archive (SRA) repository under accession numbers PRJNA1389858 and PRJNA1390117. Ca²⁺ measurements Intracellular free Ca²⁺ levels were measured in THP1 and RAW264.7 cells using Fluo-4 AM (S1060, Beyotime, China). Cells were incubated with 2 mmol/L Fluo-4 AM in serum-free medium at 37 °C for 30 min, followed by three washes with PBS at 37 °C to facilitate hydrolysis of the acetoxymethyl ester. Fluorescence was detected with an excitation wavelength of 488 nm and an emission wavelength range of 505-530 nm. Luciferase reporter assays Potential transcription factors regulating S100A9 were predicted using the JASPAR database (http://jaspar.genereg.net/). To generate mutant or wild-type S100A9 promoter luciferase reporter plasmids, the corresponding binding motifs were cloned into the pGL4-basic vector (OBiO Technology, Shanghai, China). Subsequently, 293T cells in the logarithmic growth phase were plated in 96-well plates at 70% confluence and co-transfected with the reporter plasmids and a Renilla luciferase plasmid as an internal control. Transfections were performed in 293T cells overexpressing CREB1 or carrying an empty vector. After 48 h, the cells were harvested, and luciferase activity was measured using a commercial assay kit (E1960, Promega, USA) following the manufacturer’s protocol. Mass spectrometry analysis Samples from THP1 cells in the si-NC + UDP and si-P2RY6 + UDP groups (n = 3) were maintained in serum-free medium for 24 h prior to collection. The conditioned medium was centrifuged to remove cellular debris, and the supernatant was collected for subsequent analysis. These samples were analyzed using a nano-liquid chromatography coupled with ion mobility mass spectrometry system (Timstof pro2, Thermo Fisher Scientific, USA) at the Instrumental Analysis Center of Shanghai Jiao Tong University. Mass spectrometry data were processed and analyzed to identify and quantify differentially expressed secreted proteins. Animal experiments All female BALB/c mice (RRID: IMSR_JAX:000651) (6-8 weeks old) were obtained from Shanghai Legen Biotechnology Co., Ltd. All experimental procedures involving animals were approved by the Ethics Committee of the First Hospital of Jilin University (Approval number: 20250806-06) and were conducted in compliance with relevant ethical guidelines. The mice were maintained under specific pathogen-free (SPF) conditions throughout the study, with a controlled ambient temperature of 23 ± 1 °C, relative humidity of 50 ± 10%, and a 12-h light/dark cycle. All animals were provided with standard feed regularly and had continuous access to purified water throughout the experiment. To establish tumor models, 2 × 10⁵ 4T1 cells suspended in PBS were orthotopically injected into the fourth mammary fat pad on the right flank of each mouse. For pharmacological interventions, treatment was initiated on day 6 post-inoculation. In the P2RY6-targeting experiment, mice received intraperitoneal injections of MRS2578 (3 mg/kg) (HY-13104, MedChemExpress, USA) or vehicle (DMSO) every 3 days. For chemotherapy, paclitaxel (PTX, 3 mg/kg) (HY-B0015, MedChemExpress, USA) or vehicle (DMSO) was administered intraperitoneal every 2 days. In the S100A9-targeting experiment, anti-S100A9 (50 µg/per mouse) (SinoBiological, China) or vehicle (DMSO) was injected intraperitoneal every 3 days. Tumor growth was monitored by measuring the longest (L) and shortest (W) diameters of the tumors, and tumor volume (V) was calculated using the formula: V = 0.5 × L × W². Mice were euthanized 3 weeks after tumor cell inoculation, and tumors were excised and weighed for further analysis. Statistical analysis All statistical analyses were conducted using GraphPad Prism 8.0 (La Jolla, CA, USA) and SPSS software 17.0 (IBM. Chicago, IL, USA). Data are presented as mean ± standard deviation (SD). Differences between two groups were assessed using an unpaired Student’s t-test, while comparisons among multiple groups were evaluated by one-way or two-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test. All data are representative of at least three independent experiments. Significance levels are denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant. Kaplan-Meier survival curves were generated through the online KM-plotter tool (http://kmplot.com/analysis/) to assess differences in prognosis. Results Identification of P2RY6+ TAMs in TNBC To identify potential neurotransmitter receptor and neuroactive ligand‑receptor targets in TNBC TAMs, we began by analyzing scRNA-seq data GSE161529 from the Tumor Immune Single-Cell Hub 2 (TISCH2) database [21]. A total of 106 neurotransmitter receptors of eight classical neurotransmitter systems and 145 neuroactive ligand-receptors were included in the analysis (Supplementary Table 2). Twenty-three receptors showed significant expression in macrophages. To assess their prognostic relevance, we performed Kaplan-Meier analysis using clinical follow-up data from The Cancer Genome Atlas (TCGA) cohort. Thirty-four receptors were positively associated with poor prognosis in TNBC. Among the neurotransmitter receptors and neuroactive ligand‑receptors that were both significantly expressed in macrophages and linked to unfavorable outcomes in TNBC, only the UDP-sensitive purinergic receptor P2RY6 satisfied both conditions. We therefore selected P2RY6 for further investigation. A Venn diagram outlines the screening workflow for P2RY6 (Fig. 1A). P2RY6 is a key neuroactive ligand‑receptor enriched in TAMs and correlates with poor prognosis in TNBC. A. Venn diagram identifying neurotransmitter receptors and neuroactive ligand‑receptors that are both significantly expressed in macrophages from scRNA-seq data GSE161529 and associated with poor prognosis in TNBC from TCGA cohort. Blue: neurotransmitter receptors and neuroactive ligand‑receptors significantly expressed in macrophages. Purple: neurotransmitter receptors linked to unfavorable outcomes in TNBC. B. UMAP visualization of scRNA-seq data GSE176078, colored by annotated cell type. C. Annotation of macrophage sub‑populations based on transcriptional profiles. D. Composition of major cell types across breast cancer molecular subtypes. E. Distribution of P2RY6 expression among different cell populations in TNBC. F. Elevated P2RY6 expression in macrophages from TNBC compared with non‑TNBC samples. G. Representative IHC staining showing P2RY6 expression in human TNBC tissues. Scale bar: 50 μm. H. Immunofluorescence co‑staining of P2RY6, the TAM marker CD163, and the epithelial marker EPCAM in human TNBC tissues. Nuclei are counterstained with DAPI (blue). Scale bar: 50 μm. I. Kaplan‑Meier survival analysis of TNBC patients from the TCGA‑BRCA cohort, stratified by P2RY6 expression level To delineate the expression profile of P2RY6 within the TME, we examined scRNA-seq data from breast cancer samples in the GSE176078 cohort. Following dimensionality reduction and clustering of the raw data (Supplementary Fig. 1A), major cell clusters were annotated based on established cell-type-specific markers (Supplementary Fig. 1B). Eight principal cell types were identified: epithelial cells, NK/T cells, myeloid cells, endothelial cells, fibroblasts, B cells, pericytes, and plasma cells (Fig. 1B). Subgroup annotations were subsequently performed for myeloid cells and TNBC (Fig. 1C, Supplementary Fig. 1C). Compared with non-TNBC samples, TNBC samples contained a significantly larger proportion of macrophages (Fig. 1D, Supplementary Fig. 1D). P2RY6 expression was predominantly localized to macrophages in TNBC (Fig. 1E) and was significantly higher in the TNBC group relative to the non-TNBC group (Fig. 1F). We next generated tissue microarrays using tumor specimens from TNBC patients who underwent surgical resection at the First Hospital of Jilin University. IHC revealed that P2RY6 signaling was primarily localized to immune cells scattered throughout human TNBC tissues (Fig. 1G). Immunofluorescence analysis further demonstrated a significant positive correlation at the protein level between P2RY6 expression and CD163+ TAM infiltration (Fig. 1H). Clinicopathological analysis indicated that P2RY6 expression on TAMs was significantly associated with tumor grade, but not with patient age, menopausal status, tumor size, TNM stage, or lymph node status (Supplementary Table 3). Importantly, Kaplan-Meier survival analysis revealed that TNBC patients with higher P2RY6 expression had a significantly worse prognosis than those with lower expression (Fig. 1I). P2RY6 drives macrophages toward an M2 phenotype, thereby fueling TNBC growth via paracrine signaling As previously established, UDP serves as the endogenous ligand for P2RY6, a G protein-coupled receptor enriched in purinergic signaling pathways [12]. In this study, UDP was employed as a receptor agonist to stimulate cellular activity. To evaluate the role of P2RY6 in TNBC cell proliferation, a series of in vitro assays were performed. Human TNBC cell lines (MDA-MB-468 and MDA-MB-231) and a murine breast cancer cell line (4T1) were exposed to UDP alone or in combination with the selective P2RY6 antagonist MRS2578. EdU assays indicated that treatment with UDP or UDP together with MRS2578 did not significantly alter the clonogenic capacity of TNBC cells compared to untreated controls (Fig. 2A, Supplementary Fig. 2A). Consistent findings were obtained from CCK-8 and colony formation assays (Supplementary Fig. 2B, Supplementary Fig. 3), collectively suggesting that direct modulation of P2RY6 activity in tumor cells does not exert a substantial effect on the proliferative behavior. P2RY6 drives macrophage polarization toward an M2-like phenotype. A. Proliferative response of MDA-MB-468 cells following UDP (100 µM) -induced P2RY6 activation or MRS2578 (1 µM) -mediated P2RY6 inhibition, evaluated by EdU assay. Scale bar: 80 μm. B. Schematic representation of the experimental model for macrophage polarization induction. C-D. qRT-PCR analysis of macrophage polarization marker expression under distinct polarization conditions in THP1 cells. E-F. Western blot and qRT-PCR detection of P2RY6 expression changes in polarized macrophages. G. qRT-PCR assessment of macrophage polarization markers upon P2RY6 knockdown. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant Based on the observations, we shifted our focus to investigating the influence of P2RY6+ TAMs on TNBC growth and the mechanisms involved. Given the prevalence of pro-tumorigenic M2-like TAMs within the TME, we postulated that P2RY6 might facilitate macrophage polarization toward an M2-like phenotype. To test this, we utilized the human THP1 monocytic cell line and murine RAW264.7 cells to establish in vitro models of macrophage polarization (Fig. 2B). The polarization model was validated using qRT-PCR (Fig. 2C-D, Supplementary Fig. 4A). In THP1 cells, UDP stimulation enhanced the expression of M2 markers (CD206, ARG1, TGFB), while suppressing M1 markers (CD86, iNOS) (Supplementary Fig. 4B). A similar pattern was observed in RAW264.7 cells for the respective orthologs (Cd206, Arg1, Tgfb vs. Cd86, inos) (Supplementary Fig. 4C). Subsequent qRT-PCR and western blot analyses demonstrated that P2RY6 expression was markedly elevated at both transcriptional and translational levels upon M2-like polarization (Fig. 2E-F, Supplementary Fig. 4D-E), implying a potential role for P2RY6 in regulating the polarization of macrophages toward an M2-like phenotype. To further explore this, we assessed the expression of polarization markers following P2RY6 activation by UDP. We then generated P2RY6-knockdown models in THP1 and RAW264.7 cells (Supplementary Fig. 4F). For all subsequent experiments, THP1 cells were treated with si-P2RY6-3, and RAW264.7 cells were treated with si-P2ry6-3, as these siRNAs consistently achieved the highest knockdown efficiency. Upon UDP stimulation, loss of P2RY6 led to upregulation of M1 markers and downregulation of M2-associated genes in both cell types (Fig. 2G, Supplementary Fig. 4G), supporting a role for P2RY6 in promoting M2-like polarization of macrophages. RNA sequencing of THP1 cells in the si-NC + UDP and si-P2RY6 + UDP groups (n = 3) followed by GSEA reinforced these findings. Gene sets related to M2-like polarization such as “RESTING_DIFFERENTIATED_VS_ALTERNATIVELY_ACT_M2_MACROPHAGE_DN” and “CLASSICAL_M1_VS_ALTERNATIVE_M2_MACROPHAGE_DN”, were significantly enriched in si-P2RY6 groups compared to si-NC groups upon UDP stimulation (Fig. 3A). P2RY6-knockdown significantly identified 27 differentially expressed genes (DEGs) (Supplementary Fig. 5A). Since soluble factors derived from M2-like TAMs are known to support tumor growth [20], we hypothesized that P2RY6-mediated polarization indirectly enhances TNBC proliferation via paracrine signaling. Conditioned medium from P2RY6-knockdown THP1 or RAW264.7 cells exhibited a reduced capacity to promote the proliferation of MDA-MB-468, MDA-MB-231, and 4T1 cells in CCK-8 and EdU assays (Fig. 3B-D, Supplementary Fig. 5B-E). Importantly, pharmacological inhibition of P2RY6 with MRS2578 similarly attenuated the pro-proliferative influence of macrophage-conditioned media on TNBC cells, confirming the specificity of P2RY6-dependent effects (Fig. 3E-F, Supplementary Fig. 6). In summary, these data identify P2RY6 as a novel regulator of macrophage polarization in the TME of TNBC that drives macrophages toward an M2-like, pro-tumor phenotype, thereby promoting tumor growth through paracrine signaling. P2RY6+ TAMs accelerate TNBC growth via paracrine signaling. A. GSEA plot based on the gene expression profiles of si-P2RY6 + UDP (100 µM) group compared with si-NC + UDP (100 µM) group (n = 3). NES, normalized enrichment score. B. Schematic illustration of the co-culture experimental setup. C-D. Proliferation of MDA-MB-468 cells treated with conditioned medium from THP1 cells transfected with si-P2RY6 or si-NC, measured by CCK-8 and EdU assays. Scale bar: 80 μm. E-F. Proliferation of MDA-MB-468 cells treated with conditioned medium from THP1 cells stimulated with UDP (100 µM) alone or UDP (100 µM) combined with the P2RY6 inhibitor MRS2578 (1 µM), analyzed by CCK-8 and EdU assays. Scale bar: 80 μm. *p < 0.05, **p < 0.01, ***p < 0.001 P2RY6 modulates the secretory profile of macrophages through the calcium signaling pathway To elucidate the molecular mechanism by which P2RY6 regulates macrophage polarization, we first examined the signaling pathway. P2RY6 activation triggers the canonical Gq/phospholipase C-β (Gq/PLC-β) pathway, generating inositol 1,4,5-trisphosphate (IP3) to mediate calcium influx, is a key event in macrophage activation [22]. Transcriptome analysis of THP1 cells revealed that si-P2RY6 significantly downregulated calcium-related pathways compared to the si-NC upon UDP stimulation (Fig. 4A). Consistent with this, calcium imaging using Fluo-4 AM demonstrated reduced intracellular Ca2+ fluorescence in the si-P2RY6 group compared to the si-NC group in THP1 cells (Fig. 4B-C, Supplementary Fig. 7A-B). P2RY6 regulates S100A9 production through the Ca²⁺ signaling pathway. A. GSEA using hallmark gene sets was performed to compare the THP1 si-P2RY6 group and si-NC group treated with UDP (100 µM) for 24 h (n = 3). NES, normalized enrichment score. B. Intracellular Ca²⁺ levels were monitored using the fluorescent Ca²⁺ indicator Fluo‑4 AM in THP1 cells. Scale bar: 80 μm. C. Quantitative analysis of fluorescence intensity. D. Cell-cell communication network illustrating the interaction number and interaction weights/strength between macrophage subsets and malignant cell clusters, derived from scRNA-seq data GSE176078. E. Venn diagram identifying downregulated secretory proteins in UDP (100 µM) ‑treated THP1 si-P2RY6 cells compared with UDP (100 µM) ‑treated THP1 si-NC cells, based on mass spectrometry (n = 3). Green: downregulated differentially expressed proteins in the THP1 si-P2RY6 vs. the THP1 si-NC cells treated with UDP (100 µM). Blue: differentially expressed secretory proteins. F. Elevated expression of S100A9 and P2RY6 in macrophages from TNBC compared with non‑TNBC samples. G. Correlation of P2RY6 and S100A9 gene expression. H-I. ELISA and qRT‑PCR analysis of S100A9 secretion and expression following pretreatment with the PLC inhibitor U73122 (10 µM), the IP₃ receptor inhibitor 2‑APB (20 µM), or the intracellular Ca²⁺ chelator BAPTA‑AM (10 µM) in UDP (100 µM) ‑stimulated THP1 cells. J-K. ELISA and qRT‑PCR detection of S100A9 secretion and expression in UDP (100 µM) ‑stimulated THP1 cells after transfection with si-P2RY6 or si-NC. *p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant To systematically characterize cell-cell communication involving macrophages, we conducted intercellular communication analysis using CellChat based on the scRNA-seq dataset GSE176078. This included quantifying the number of ligand-receptor interactions and assessing the overall interaction weights/strength between distinct macrophage subsets and malignant cells (Fig. 4D, Supplementary Fig. 7C-D). Notably, significant communication was observed specifically between macrophages and malignant cells. The findings suggest that macrophages modulate malignant cells through paracrine signaling. Analysis of mass spectrometry data identified 382 differentially expressed proteins in UDP-treated THP1 cells from the si-P2RY6 group compared to the si-NC group, with 301 proteins downregulated (Supplementary Fig. 7E, Supplementary Table 4). Among the differentially expressed proteins, 37 were secretory proteins, of which 20 were downregulated (Fig. 4E, Supplementary Table 5). Previous studies have demonstrated the oncogenic role of S100A9, linking it to the pathogenesis of various cancers including hepatocellular carcinoma, colorectal cancer, and bladder cancer [17]. Furthermore, scRNA-seq data from the GSE176078 dataset revealed that, similar to P2RY6, S100A9 is significantly expressed in macrophages in TNBC (Fig. 4F, Supplementary Fig. 7F-G). A significant correlation was also observed between the gene expression levels of P2RY6 and S100A9 (Fig. 4G). Based on the observations, S100A9 was selected for further study. To confirm that P2RY6 regulates S100A9 secretion through the Ca²⁺ pathway, macrophages were treated with the PLC inhibitor U73122, the IP₃ receptor inhibitor 2-APB, or the intracellular calcium chelator BAPTA-AM. S100A9 secretion and mRNA expression were measured by ELISA and qRT‑PCR, respectively. Inhibition at each step of the PLC-IP₃-Ca²⁺ signaling pathway resulted in downregulation of S100A9 (Fig. 4H-I). Consistent with the findings, knockdown of P2RY6 in macrophages similarly reduced S100A9 levels (Fig. 4J-K). P2RY6-PLC-IP₃-Ca²⁺/CREB1 pathway drives S100A9 expression Elevated intracellular Ca²⁺ signaling acts as a key trigger for gene expression regulation [23]. However, as Ca²⁺ cannot directly bind DNA, its biological effects require transduction by downstream calcium-sensitive transcription factors. Our study has established the role of the P2RY6-PLC-IP₃-Ca²⁺ pathway in driving S100A9 secretion, suggesting a possible additional layer of long-term transcriptional control over the protein. Given the central role of CREB1 in converting Ca²⁺ signals into transcriptional output and its established function in inflammatory gene expression [24], we hypothesize that CREB1 acts as a downstream transcription factor within the pathway, directly regulating S100A9 transcription. The CREB1-mediated induction of S100A9 may enhance its secretion by TAMs, thereby supporting the growth of TNBC. Western blot analysis revealed that the ratio of phosphorylated CREB1 to total CREB1 (p-CREB1 (Ser133)/T-CREB1) was reduced in UDP-treated macrophages following P2RY6 knockdown (Fig. 5A), confirming that P2RY6 activation induces CREB1 phosphorylation. Moreover, pharmacological inhibitors targeting individual steps of the PLC-IP₃-Ca²⁺ pathway were employed. In addition to the calcium chelator BAPTA-AM, both the PLC inhibitor U73122 and the IP₃ receptor inhibitor 2-APB markedly attenuated CREB1 phosphorylation in UDP-stimulated THP1 cells (Fig. 5B). We next explored whether CREB1 directly binds to the S100A9 promoter. Using the JASPAR database, we predicted the CREB1 binding motif (Fig. 5C) and identified potential binding sites within the S100A9 promoter region (Fig. 5D), suggesting transcriptional regulation of S100A9 by CREB1. To further verify this, a dual-luciferase reporter assay was performed. 293T cells overexpressing CREB1 or empty vector were transfected with either wild-type (WT) or mutant (MUT) S100A9 promoter constructs. Luciferase activity analysis confirmed that CREB1 transactivates the S100A9 promoter, with significantly higher activity observed for the WT promoter compared to the MUT promoter in CREB1-overexpressing cells (Fig. 5E). To further examine the impact of CREB1 on macrophage polarization, we used the specific inhibitor 666 -15 and measured polarization markers via qRT-PCR. Upon UDP-induced P2RY6 activation, CREB1 inhibition attenuated the increase in M2 markers (CD206, ARG1, TGFB) and countered the decrease in M1 markers (CD86 and iNOS) in THP1 cells (Fig. 5F). These data suggest that CREB1 is involved in promoting an M2-like polarization phenotype in macrophages. P2RY6-PLC-IP₃-Ca²⁺ promotes S100A9 secretion via CREB1-dependent transcription. A. P2RY6 knockdown attenuates UDP (100 µM) ‑stimulated CREB1 phosphorylation in THP1 cells, as assessed by western blot. B. Pharmacological inhibition of the PLC‑IP₃‑Ca²⁺ pathway (using U73122 (10 µM), 2‑APB (20 µM) or BAPTA‑AM (10 µM)) reduces UDP (100 µM) ‑induced CREB1 phosphorylation in THP1 cells by western blot. C-D. Putative CREB1‑binding motifs in the S100A9 promoter region predicted by the JASPAR database. E. Luciferase reporter assay of S100A9 promoter activity upon co‑expression with CREB1, tested with serial truncations or site‑directed mutations. F. Treatment with the CREB1 inhibitor 666‑15 (100 nM) suppressed the increase in M2 markers (CD206, ARG1, TGFB) and the reduction in M1 markers (CD86 and iNOS) triggered by UDP (100 µM)- stimulated P2RY6 activation in THP1 cells. G. Neutralization of S100A9 in THP1 conditioned medium with an anti‑S100A9 antibody (2 µg/mL) abolishes its pro‑proliferative effect on MDA‑MB‑468 cells, evaluated by EdU assay. Scale bar: 80 μm. H. Proliferation of MDA‑MB‑468 cells treated with rhS100A9 (1 µg/mL) or an anti‑S100A9 neutralizing antibody (2 µg/mL), evaluated by EdU assay. Scale bar: 80 μm. *p < 0.05, **p < 0.01, ***p < 0.001 We further assessed the effect of S100A9 on TNBC growth in vitro. As S100A9 is secreted, a neutralizing antibody was used to block its function. EdU and CCK-8 assays showed that conditioned medium from THP1 cells promoted TNBC cell proliferation relative to the 1640 medium control. The pro-proliferative effect was largely abolished by anti-S100A9 treatment of the macrophage conditioned medium [25, 26] (Fig. 5G, Supplementary Fig. 8A-C), indicating that macrophage-secreted S100A9 is a pivotal driver of TNBC growth within the TME. To further validate the growth-promoting role of S100A9, TNBC cells were stimulated directly with rhS100A9. Both EdU and CCK-8 assays revealed significantly increased EdU-positive cell counts and OD values in the rhS100A9-treated group, confirming enhanced proliferation. Conversely, addition of the S100A9-neutralizing antibody markedly suppressed the effect (Fig. 5H, Supplementary Fig. 8D-F). S100A9 promotes TNBC growth via activation of the NF-κB pathway, which is mediated by the TLR4 and RAGE receptors S100A9 is known to signal through interactions with its major receptors, TLR4 and RAGE [27]. IHC staining revealed higher expression of TLR4 and RAGE in TNBC tissues relative to adjacent normal tissues (Fig. 6A, C). Immunofluorescence results demonstrated the protein-level co-localization of TLR4 and RAGE and EpCAM in TNBC tissues (Fig. 6B, D). Additionally, TLR4 and RAGE expression was confirmed via immunofluorescence in MDA-MB-468 and MDA-MB-231 cells (Fig. 6E, Supplementary Fig. 9A). We next assessed the functional contribution of S100A9 to tumor growth via TLR4 and RAGE using specific inhibitors (TAK-242 for TLR4; FPS-ZM1 for RAGE). EdU and CCK-8 assays demonstrated that S100A9-enhanced tumor cell proliferation was abolished upon inhibition of either receptor (Fig. 6F, Supplementary Fig. 9B-D). S100A9 promotes TNBC growth by activating the NF‑κB pathway through TLR4 and RAGE receptors. A. Representative IHC staining of TLR4 in human TNBC tissues and paired adjacent non‑tumor tissues. Scale bar: 50 μm. B. Immunofluorescence co‑localization of TLR4 and the epithelial marker EPCAM in human TNBC and adjacent tissues. Scale bar: 50 μm. C. IHC detection of RAGE expression in human TNBC tissues and matched non‑tumor tissues. Scale bar: 50 μm. D. Immunofluorescence co‑staining of RAGE and EPCAM in TNBC and adjacent specimens. Scale bar: 50 μm. E. Immunofluorescence visualization of TLR4 and RAGE expression in MDA‑MB‑468 cells. Scale bar: 20 μm. F. EdU proliferation assay demonstrating that pharmacological inhibition of TLR4 (TAK‑242; 10 µM) or RAGE (FPS‑ZM1; 10 µM) abrogates rhS100A9 (1 µg/mL) ‑induced proliferation of MDA‑MB‑468 cells. Scale bar: 80 μm. G. GSEA of RNA‑seq data from MDA‑MB‑468 cells stimulated with rhS100A9 (1 µg/mL) for 12 h versus untreated controls (n = 3). H. Western blot analysis showing that S100A9‑induced activation of the NF‑κB pathway in MDA‑MB‑468 cells is mediated by TLR4 and RAGE, and is attenuated by specific receptor inhibitors. I. qRT‑PCR analysis confirming that S100A9 upregulates NF‑κB target genes TNFA and BCL-2 in MDA‑MB‑468 cells in a TLR4/RAGE‑dependent manner, an effect reversed by receptor blockade. *p < 0.05, **p < 0.01, ***p < 0.001 To investigate the impact of S100A9 on tumor cell growth, we performed RNA sequencing of MDA-MB-468 cells treated with rhS100A9 versus control (n = 3). S100A9 treatment resulted in 256 DEGs (Supplementary Fig. 9E). Functional enrichment analysis revealed that rhS100A9 treatment led to significant enrichment of the “GOBP_POSITIVE_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS” and “WHITFIELD_CELL_CYCLE_S” pathways in TNBC cells, suggesting a state of active proliferation (Fig. 6G). Previous studies indicate that S100A9 functions by activating the TLR4- and RAGE-dependent NF-κB signaling pathway [28, 29]. Consistent with this, western blot analysis showed upregulation of phosphorylated NF-κB (p-NF-κB) upon S100A9 stimulation, while qRT-PCR revealed increased mRNA levels of the downstream target genes TNFA and BCL-2. However, when the TLR4/RAGE receptors were inhibited, the expression of p-NF-κB and the corresponding inflammatory factors showed no significant increase even after S100A9 addition, indicating a failure to activate the pathway (Fig. 6H-I, Supplementary Fig. 9F-G). Together, the findings illustrate that S100A9, upon binding to TLR4 and RAGE receptors, activates the downstream NF-κB signaling pathway to promote the growth of TNBC. Targeting P2RY6 in vivo inhibits TNBC growth while sensitizes chemotherapy We next assessed the impact of P2RY6 on tumor growth in vivo. Consistent with in vitro observations, in an orthotopic TNBC model established in BALB/c mice (Supplementary Fig. 10A), treatment with the P2RY6 inhibitor MRS2578 led to reduced tumor volume and tumor weight compared with the control group, indicating suppression of tumor growth (Supplementary Fig. 10B-D). IHC analysis of Ki67 infiltration in tumor tissues further revealed significantly lower Ki67 levels in the inhibitor-treated group relative to controls (Supplementary Fig. 10E), supporting an anti-proliferative effect. Although chemotherapy is an approved treatment for TNBC, most patients do not achieve sustained clinical benefit [30]. To address the limitation, we evaluated the therapeutic potential of combining P2RY6 inhibition with chemotherapy in an orthotopic TNBC mouse model (Fig. 7A). Compared with P2RY6 inhibition alone, the combination of MRS2578 and paclitaxel (PTX) significantly attenuated tumor growth (Fig. 7B-D). IHC demonstrated that combined treatment markedly decreased Ki67 infiltration while increasing CC3 expression in tumor tissues (Fig. 7E), confirming a synergistic antitumor effect. Targeting the UDP-P2RY6 axis or its downstream effector S100A9 attenuates TNBC growth and sensitizes Chemotherapy in vivo. A. Schematic of the orthotopic mammary tumor model established in BALB/c mice and treated with the P2RY6 inhibitor MRS2578 (3 mg/kg, every 3 days), PTX (3 mg/kg, every 2 days), or their combination. B. Representative gross images of excised orthotopic tumors (n = 5). C-D. Quantitative analysis of orthotopic tumor volume and weight across treatment groups. E. IHC staining of Ki67 and CC3 in tumor tissues from mice treated with MRS2578, PTX, or the combination. Scale bar: 50 μm. F. Schematic of the orthotopic mammary tumor model in BALB/c mice receiving MRS2578 (3 mg/kg, every 3 days), or an anti‑S100A9 neutralizing antibody (50 µg/per mouse, every 3 days), combined with PTX (3 mg/kg, every 2 days). G. Representative gross images of orthotopic tumors (n = 5). H-I. Tumor volume and weight quantification across treatment groups. J. IHC staining of Ki67 and CC3 in tumor tissues following treatment with MRS2578, or an anti‑S100A9 neutralizing antibody, combined with PTX. Scale bar: 50 μm. *p < 0.05, **p < 0.01, ***p < 0.001 To further validate the findings in vivo, we established an orthotopic TNBC model in BALB/c mice treated with PTX, MRS2578, or an S100A9-neutralizing antibody (Fig. 7F). The smallest tumors were observed in groups receiving PTX together with either MRS2578 or the S100A9-neutralizing antibody (Fig. 7G-I). Paraffin-embedded tumor sections subjected to IHC staining showed that tumors from the combination groups exhibited the lowest Ki67 expression and the highest CC3 levels (Fig. 7J). The results demonstrate the therapeutic efficacy of targeting the P2RY6/S100A9 axis and highlight the potent tumor-suppressive activity achieved by combining chemotherapy with either P2RY6 inhibition or S100A9 neutralization. In summary, our study identifies P2RY6 as a promising therapeutic target for mitigating TNBC growth and improving chemotherapy efficiency. Discussion Neurotransmitters contribute to tumorigenesis through their interactions with neurotransmitter receptors and neuroactive ligand‑receptor systems [31]. In the present study, we demonstrate that P2RY6, a neuroactive ligand‑receptor significantly expressed on TAMs in TNBC, plays a key immunomodulatory role. P2RY6+ TAMs are associated with higher tumor grade and poorer prognosis, highlighting their clinical relevance. UDP‑mediated activation of P2RY6+ TAMs triggers M2‑like polarization and promotes secretion of S100A9 via the PLC-IP₃-Ca²⁺/CREB1 signaling axis. By binding to TLR4/RAGE receptors on tumor cells, S100A9 acts as a paracrine factor to activate the NF-κB pathway, consequently accelerating TNBC growth (Fig. 8). The schematic illustrates how P2RY6+ TAMs drives TNBC growth. Specifically, UDP‑driven activation of P2RY6 on TAMs initiates the PLC-IP₃-Ca²⁺/CREB1 signaling cascade, fostering M2‑like polarization and stimulating production and release of S100A9. The secreted S100A9 engages TLR4 and RAGE receptors on TNBC cells, leading to NF‑κB activation and thereby accelerating tumor growth TAMs, the predominant immune cells in TNBC, are pivotal players in the context [32]. TAMs polarize into either M1 or M2 phenotypes in response to environmental signals, with the M2-like TAMs being the major population that promotes tumor progression, tumorigenesis, and immunosuppression [33]. Within the TME, extracellular nucleotides released from damaged cells act as danger signals that alert the immune system [34]. THP1 cells, derived from human acute monocytic leukemia, can be differentiated into adherent macrophages with PMA and have been extensively employed to study macrophage polarization and phagocytosis [35, 36]. RAW264.7 cells, a murine macrophage line, are similarly widely used for inflammation and immune regulation studies [37, 38]. The parallel use of human and murine cells allows cross-species comparison, strengthening the generalizability of our conclusions. The P2 purinergic receptor P2RY6, which is specifically activated by UDP, plays a role in modulating immune responses and inflammation [39–41]. Supporting this, a UDP-rich TME in pancreatic cancer has been shown to support the infiltration of P2RY6+ TAMs, which fosters immunosuppression and confers resistance to immunotherapy [42]. In this study, we further investigated P2RY6 as a potential regulator of macrophage polarization in TNBC. P2RY6 exhibits significant expression on TAMs, and the expression level correlates with the degree of M2-like TAMs infiltration in TNBC tissues. Clinicopathological evaluation revealed a significant correlation between TAM-associated P2RY6 expression levels and tumor grade. Importantly, altering P2RY6 activity in TNBC cells did not significantly affect tumor growth, indicating that P2RY6 is unlikely to directly promote cancer cell proliferation. Conversely, knockdown of P2RY6 in macrophages promoted a shift toward the M1 phenotype, characterized by elevated M1 marker expression and reduced M2 markers. The macrophage reprogramming resulted in enhanced immune activation and significantly suppressed tumor growth. Collectively, the findings demonstrate that P2RY6+ TAMs influence tumor growth by modulating the communication between tumor cells and the immune system. Inflammatory responses are triggered by diverse stimuli through calcium-dependent mechanisms [43]. Typically, Ca²⁺ signaling is initiated by the release of Ca²⁺ from endoplasmic reticulum stores. The resulting rise in cytoplasmic free Ca²⁺ promotes the activation of downstream kinases such as PLC [44]. The transcription factor CREB1 acts as a classical effector in calcium signaling pathways, regulating the expression of genes involved in various physiological and pathological processes [45]. In this study, P2RY6 knockdown significantly reduced intracellular Ca²⁺ levels and CREB1 activation in response to UDP stimulation in macrophages. The P2RY6-induced CREB1 activation was dependent on the PLC-IP₃-Ca²⁺ pathway, as its stepwise inhibition effectively blocked the process. Moreover, CREB1 inhibition impeded the M2-like polarization of macrophages triggered by UDP-activated P2RY6. Collectively, our findings demonstrate that UDP stimulation promotes M2-like polarization of P2RY6⁺ TAMs via a PLC-IP₃-Ca²⁺/CREB1 signaling axis. While TAMs are recognized drivers of TNBC progression, primarily through paracrine signaling within the immune microenvironment, the specific cytokines involved are not well defined. Our secretome analysis of P2RY6-knockdown THP1 cells revealed S100A9 as a key effector. Although immune-mediated functions are conceivable, S100A9 likely acts through direct receptor binding [17]. While prior studies have linked S100A9 to malignancy in various cancers, including lung adenocarcinoma, hepatocellular carcinoma, pancreatic cancer and colon cancer [46–49], our work establishes its pro-tumorigenic role in TNBC. Mechanistically, P2RY6⁺ TAMs enhance S100A9 secretion, which then activates the NF-κB pathway in TNBC cells by engaging TLR4/RAGE receptors, thereby driving tumor growth in a paracrine manner. Targeted therapy is considered a promising approach in cancer treatment [50]. Blocking the UDP/P2RY6 axis has been shown to remodel the pre-metastatic niche by reducing neutrophil recruitment, thereby preventing melanoma lung metastasis [51]. Similarly, the inhibition of S100A9 or its receptors has been found to significantly suppress hepatocellular carcinoma progression [25]. The clinical challenge in TNBC lies in the transient and limited benefit of chemotherapy for most patients, despite its broad antitumor efficacy [52, 53]. Enhancing chemosensitivity by targeting the immunosuppressive TME, particularly through inhibiting the infiltration or function of immunosuppressive cells, presents a rational combination strategy. Our findings directly contribute to the strategy by identifying a targetable axis within TAMs. Strategies focused on the P2RY6/S100A9 axis in TAMs represent a promising dual-purpose approach, achieving direct antitumor effects and potentially sensitizing tumors to conventional chemotherapy. In summary, our study identifies the function of the purinergic receptor P2RY6, advancing our understanding of how neuroactive ligand‑receptors contribute to immune modulation. Specifically, we show that P2RY6 is significantly expressed in TAMs within the TME of TNBC. Activation of P2RY6 by UDP initiates the PLC-IP₃-Ca²⁺/CREB1 signaling cascade, which drives TAMs toward an M2‑like phenotype and promotes secretion of the effector protein S100A9. The TAM‑derived S100A9 then engages TLR4 and RAGE receptors on TNBC cells, activating the NF‑κB pathway and fueling tumor growth. Importantly, pharmacological inhibition of P2RY6 or neutralization of S100A9 blunts the pro‑tumorigenic effects in TAMs and synergizes with chemotherapy to suppress tumor growth. Together, the results highlight the UDP-P2RY6 axis as promising therapeutic targets in TNBC. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements Not applicable. Author contributions X.W.: Writing-original draft, Validation, Resources, Writing-review and editing, Formal analysis. M.Y.M.: Methodology, Supervisions, Investigation. M.Y.Z.: Software, Data curation. H.L.: Validation. Y.L.: Formal analysis. Y.Z.: Investigation. B.H.: Supervision, Project administration, Writing-review and editing, Conceptualization. Funding This work was supported by the Department of Science and Technology of Jilin Province under Grant [number 20230401091YY]. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate This study was conducted in compliance with the principles of the Declaration of Helsinki. All experiments with human tissue samples were approved by the Ethics Committee of the First Hospital of Jilin University (Approval Number: 2023-727). Animal experiments were approved by the Ethics Committee of the First Hospital of Jilin University (Approval Number: 20250806-06). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement No datasets were generated or analysed during the current study.